Changes in serum IGF-1 level and tumor VEGF expression in mice with colorectal cancer under hyperglycemic conditions

Molecular Medicine Reports

Volumn 7, Issue 4, 2013, Pages 1361-1365

  Cao, Hong ^a,b   Jin, Chunhui ^c   Huang, Defang ^b   Liu, Chao ^d   Sun, Daoqi ^b   Tan, Cheng ^e   Zhu, Xiaoming ^c   Fei, Yajun ^c  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b NANTONG UNIVERSITY   (China)

^c Wuxi Hospital of Traditional Chinese Medicine   (China)

^d THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^e JIANGSU INSTITUTE OF NUCLEAR MEDICINE   (China)

Author keywords

Colorectal cancer; Diabetes mellitus; IGF 1; Mice; Type 2; VEGF

Indexed keywords

SOMATOMEDIN C; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENETIC TRANSCRIPTION; HYPERGLYCEMIA; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; RISK FACTOR; TUMOR VOLUME; UPREGULATION;

ANIMALS; COLORECTAL NEOPLASMS; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERGLYCEMIA; INSULIN-LIKE GROWTH FACTOR I; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875271169     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1339     Document Type: Article

References (19)

1. Larsson SC, Orsini N and Wolk A: Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97: 1679-1687, 2005.
2. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III and Fuchs CS: Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 21: 433-440, 2003.
3. Levi F, Pasche C, Lucchini F and La Vecchia C: Diabetes mellitus, family history, and colorectal cancer. J Epidemiol Community Health 56: 479-480, 2002.
4. Giouleme O, Diamantidis MD and Katsaros MG: Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J Gastroenterol 17: 444-448, 2011.
5. Pechlivanis S, Bermejo JL, Pardini B, et al: Genetic variation in adipokine genes and risk of colorectal cancer. Eur J Endocrinol 160: 933-940, 2009.
6. Kobayashi M, Ohno T, Tsuchiya T and Horio F: Characterization of diabetes-related traits in MSM and JF1 mice on high-fat diet. J Nutr Biochem 15: 614-621, 2004.
7. Ezzat VA, Duncan ER, Wheatcroft SB and Kearney MT: The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obes Metab 10: 198-211, 2008.
8. Ooi GT, Tseng LY, Tran MQ and Rechler MM: Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol Endocrinol 6: 2219-2228, 1992.
9. Guastamacchia E, Resta F, Triggiani V, et al: Evidence for a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer: role of hormones, growth factors and specific receptors. Curr Drug Targets Immune Endocr Metabol Disord 4: 59-66, 2004.
10. Lee CT, Park KH, Adachi Y, et al: Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther 10: 57-63, 2003.
11. Bai HZ, Pollman MJ, Inishi Y and Gibbons GH: Regulation of vascular smooth muscle cell apoptosis: Modulation of bad by a phosphatidylinositol 3-kinase-dependent pathway. Circ Res 85: 229-237, 1999.
12. Matsui T, Li L, del Monte F, et al: Adenoviral gene transfer of activated phosphatidylinositol 3'-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 100: 2373-2379, 1999.
13. Ibrahim YH and Yee D: Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res 14: 261-269, 2004.
14. Kohda M, Hoshiya H, Katoh M, et al: Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Mol Carcinog 31: 184-191, 2001.
15. Lin LJ, Zheng CQ, Jin Y, Ma Y, Jiang WG and Ma T: Expression of survivin protein in human colorectal carcinogenesis. World J Gastroenterol 9: 974-977, 2003.
16. Minagawa N, Nakayama Y, Hirata K, et al: Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer. Anticancer Res 22: 2957-2963, 2002.
17. Hashim AF, Al-Janabi AA, Mahdi LH, Al-Toriahi KM and Yasseen AA: Vascular endothelial growth factor (VEGF) receptor expression correlates with histologic grade and stage of colorectal cancer. Libyan J Med 5: 2010.
18. Chang CK and Ulrich CM: Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia 46: 595-607, 2003
19. Grulich-Henn J, Ritter J, Mesewinkel S, Heinrich U, Bettendorf M and Preissner KT: Transport of insulin-like growth factor-1 across endothelial cell monolayers and its binding to the subendothelial matrix. Exp Clin Endocrinol Diabetes 110: 67-73, 2002.